Compound class:
Synthetic organic
Comment: S416 is an inhibitor of dihydroorotate dehydrogenase (DHODH) [1]. It has been explored for antiviral activity against RNA viruses, including SARS-CoV-2, based on the rationale that viruses depend on host pyrimidine synthesis to maintain their replication, and that therefore inhibiting a crucial step in this synthetic pathway should limit viral replication. Mechanistically, S416 binds at the putative ubiquinone binding tunnel within the DHODH active site.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
S416 is a more potent inhibitor of DHODH than teriflunomide in vitro [1]. Antiviral potency (EC50) for S416 vs. SARS-CoV-2 is 17 nM at MOI = 0.05. In comparison teriflunomide had an anti-SARS-CoV-2 EC50 of 26.06 μM, the EC50 for favipiravir was 66.85 μM and for brequinar it was 0.123 μM. |
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|